Adcock Ingram's Urizone receives legal protection as the court halts Cipla's Furizome, citing trademark infringement.
You must be a subscriber to access all of this content.
Explore the Aspen Pharmacare manufacturing dispute and its potential impact on core earnings for the 2025 financial year.
You must be a subscriber to access all of this content.
Health Minister Aaron Motsoaledi discusses the NHI advertising campaign designed to address misinformation and support health efforts.
You must be a subscriber to access all of this content.
Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.
You must be a subscriber to access all of this content.
Read about the Clicks interim results that reveal a 13.2% rise in headline earnings per share and significant market achievements.
You must be a subscriber to access all of this content.
Get insights on the Trump drug price executive order and how it may reshape timelines for drug price negotiations.
You must be a subscriber to access all of this content.